These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 17603846)

  • 1. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine.
    Rojas OL; Caicedo L; Guzmán C; Rodríguez LS; Castañeda J; Uribe L; Andrade Y; Pinzón R; Narváez CF; Lozano JM; De Vos B; Franco MA; Angel J
    Viral Immunol; 2007; 20(2):300-11. PubMed ID: 17603846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
    J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Immunogenicity and Safety of a Human Rotavirus Vaccine RIX4414 in Singaporean Infants.
    Phua KB; Lim FS; Quak SH; Lee BW; Teoh YL; Suryakiran PV; Han HH; Bock HL
    Ann Acad Med Singap; 2016 Feb; 45(2):44-50. PubMed ID: 27125345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
    Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
    Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.
    Li RC; Li YP; Mo ZJ; Luo D; Huang T; Kong JL; Wang LH; Song NS; Liu A; Zhang H; Liao X; Karkada N; Han HH
    Hum Vaccin Immunother; 2013 Aug; 9(8):1638-42. PubMed ID: 23807360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants.
    Araujo EC; Clemens SA; Oliveira CS; Justino MC; Rubio P; Gabbay YB; da Silva VB; Mascarenhas JD; Noronha VL; Clemens R; Gusmão RH; Sanchez N; Monteiro TA; Linhares AC
    J Pediatr (Rio J); 2007; 83(3):217-24. PubMed ID: 17380232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.
    Kim JS; Bae CW; Lee KY; Park MS; Choi YY; Kim KN; Kim JD; Park WS; Sin JB; Kim EA; Lee SG; Kim CS; Cha SH; Hong YJ; Shin SM; Shim GH; Choi KM; Yang JW; Liu A; Suryakiran PV; Han HH
    Hum Vaccin Immunother; 2012 Jun; 8(6):806-12. PubMed ID: 22699440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
    Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
    J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial.
    Bernstein DI; Sack DA; Rothstein E; Reisinger K; Smith VE; O'Sullivan D; Spriggs DR; Ward RL
    Lancet; 1999 Jul; 354(9175):287-90. PubMed ID: 10440305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
    Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine.
    Ward RL; Bernstein DI; Smith VE; Sander DS; Shaw A; Eiden JJ; Heaton P; Offit PA; Clark HF
    J Infect Dis; 2004 Jun; 189(12):2290-3. PubMed ID: 15181577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotavirus specific plasma secretory immunoglobulin in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine.
    Herrera D; Vásquez C; Corthésy B; Franco MA; Angel J
    Hum Vaccin Immunother; 2013 Nov; 9(11):2409-17. PubMed ID: 23839157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.
    Clark HF; Burke CJ; Volkin DB; Offit P; Ward RL; Bresee JS; Dennehy P; Gooch WM; Malacaman E; Matson D; Walter E; Watson B; Krah DL; Dallas MJ; Schödel F; Kaplan kM; Heaton P
    Pediatr Infect Dis J; 2003 Oct; 22(10):914-20. PubMed ID: 14551493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum IgA levels induced by rotavirus natural infection, but not following immunization with the RRV-TV vaccine (Rotashield), correlate with protection.
    González R; Franco M; Sarmiento L; Romero M; Schael IP
    J Med Virol; 2005 Aug; 76(4):608-12. PubMed ID: 15977224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants.
    Vesikari T; Karvonen A; Korhonen T; Espo M; Lebacq E; Forster J; Zepp F; Delem A; De Vos B
    Vaccine; 2004 Jul; 22(21-22):2836-42. PubMed ID: 15246619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.
    Vesikari T; Prymula R; Schuster V; Tejedor JC; Cohen R; Bouckenooghe A; Damaso S; Han HH
    Pediatr Infect Dis J; 2012 May; 31(5):509-13. PubMed ID: 22228235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The memory B cell subset responsible for the secretory IgA response and protective humoral immunity to rotavirus expresses the intestinal homing receptor, alpha4beta7.
    Williams MB; Rosé JR; Rott LS; Franco MA; Greenberg HB; Butcher EC
    J Immunol; 1998 Oct; 161(8):4227-35. PubMed ID: 9780197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
    Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD;
    Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of Thai infants with rhesus-human reassortant tetravalent oral rotavirus vaccine.
    Simasathien S; Migasena S; Samakoses R; Pitisuttitham P; Sangaroon P; Aree C; Bishop R; Bugg H; Davidson BL; Vesikari T
    Pediatr Infect Dis J; 1994 Jul; 13(7):590-6. PubMed ID: 7970945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
    Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
    Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.